Alkermes plc (ALKS)
USD 26.59
(-7.71%)
USD 26.59
(-7.71%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 933.53 Million USD | 1.45% |
| 2022 | 920.22 Million USD | 0.91% |
| 2021 | 911.9 Million USD | 3.3% |
| 2020 | 882.74 Million USD | 22.61% |
| 2019 | 719.96 Million USD | 10.13% |
| 2018 | 653.72 Million USD | 9.98% |
| 2017 | 594.41 Million USD | 14.99% |
| 2016 | 516.94 Million USD | -4.53% |
| 2015 | 541.46 Million USD | 3.25% |
| 2014 | 524.43 Million USD | 1.26% |
| 2013 | 517.91 Million USD | -10.91% |
| 2012 | 581.36 Million USD | 862.05% |
| 2011 | 60.43 Million USD | -41.32% |
| 2010 | 102.98 Million USD | -21.74% |
| 2009 | 131.59 Million USD | -62.51% |
| 2008 | 350.99 Million USD | -3.88% |
| 2007 | 365.16 Million USD | -17.75% |
| 2006 | 443.94 Million USD | 32.62% |
| 2005 | 334.76 Million USD | 72.47% |
| 2004 | 194.09 Million USD | -25.56% |
| 2003 | 260.74 Million USD | 4.01% |
| 2002 | 250.68 Million USD | 3.21% |
| 2001 | 242.88 Million USD | -1.26% |
| 2000 | 245.99 Million USD | 329.88% |
| 1999 | 57.22 Million USD | 48.36% |
| 1998 | 38.57 Million USD | 50.99% |
| 1997 | 25.54 Million USD | 14.55% |
| 1996 | 22.3 Million USD | 43.87% |
| 1995 | 15.5 Million USD | 7.64% |
| 1994 | 14.4 Million USD | 128.57% |
| 1993 | 6.3 Million USD | 320.0% |
| 1992 | 1.5 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 869.13 Million USD | -6.9% |
| 2024 Q3 | 863.18 Million USD | -6.46% |
| 2024 Q2 | 922.83 Million USD | 6.18% |
| 2023 Q3 | 923.64 Million USD | 1.86% |
| 2023 Q2 | 906.74 Million USD | -1.13% |
| 2023 Q4 | 933.53 Million USD | 1.07% |
| 2023 Q1 | 917.15 Million USD | -0.33% |
| 2023 FY | 933.53 Million USD | 1.45% |
| 2022 Q1 | 902.45 Million USD | -1.04% |
| 2022 Q2 | 875.09 Million USD | -3.03% |
| 2022 Q3 | 899.04 Million USD | 2.74% |
| 2022 Q4 | 920.22 Million USD | 2.36% |
| 2022 FY | 920.22 Million USD | 0.91% |
| 2021 FY | 911.9 Million USD | 3.3% |
| 2021 Q3 | 899.26 Million USD | 7.1% |
| 2021 Q2 | 839.66 Million USD | 1.52% |
| 2021 Q4 | 911.9 Million USD | 1.41% |
| 2021 Q1 | 827.06 Million USD | -6.31% |
| 2020 Q2 | 740.49 Million USD | -2.94% |
| 2020 Q4 | 882.74 Million USD | 11.39% |
| 2020 FY | 882.74 Million USD | 22.61% |
| 2020 Q1 | 762.92 Million USD | 5.97% |
| 2020 Q3 | 792.46 Million USD | 7.02% |
| 2019 Q1 | 654.39 Million USD | 0.1% |
| 2019 Q4 | 719.96 Million USD | 4.37% |
| 2019 Q3 | 689.81 Million USD | 4.42% |
| 2019 Q2 | 660.58 Million USD | 0.95% |
| 2019 FY | 719.96 Million USD | 10.13% |
| 2018 Q1 | 580.66 Million USD | -2.31% |
| 2018 Q4 | 653.72 Million USD | 7.17% |
| 2018 Q3 | 609.99 Million USD | 2.81% |
| 2018 Q2 | 593.33 Million USD | 2.18% |
| 2018 FY | 653.72 Million USD | 9.98% |
| 2017 FY | 594.41 Million USD | 14.99% |
| 2017 Q4 | 594.41 Million USD | 5.95% |
| 2017 Q3 | 561.04 Million USD | 6.01% |
| 2017 Q2 | 529.25 Million USD | 3.14% |
| 2017 Q1 | 513.12 Million USD | -0.74% |
| 2016 FY | 516.94 Million USD | -4.53% |
| 2016 Q4 | 516.94 Million USD | 3.87% |
| 2016 Q1 | 529.8 Million USD | -2.15% |
| 2016 Q2 | 541.76 Million USD | 2.26% |
| 2016 Q3 | 497.68 Million USD | -8.14% |
| 2015 Q3 | 514.15 Million USD | -0.3% |
| 2015 Q2 | 515.68 Million USD | 2.25% |
| 2015 Q4 | 541.46 Million USD | 5.31% |
| 2015 FY | 541.46 Million USD | 3.25% |
| 2015 Q1 | 504.35 Million USD | -3.83% |
| 2014 Q3 | 504.26 Million USD | -0.3% |
| 2014 Q2 | 505.76 Million USD | 1.97% |
| 2014 Q1 | 495.97 Million USD | -3.21% |
| 2014 FY | 524.43 Million USD | 1.26% |
| 2014 Q4 | 524.43 Million USD | 4.0% |
| 2013 Q1 | 517.91 Million USD | 5.31% |
| 2013 Q4 | 512.4 Million USD | 3.42% |
| 2013 Q3 | 495.46 Million USD | -0.09% |
| 2013 Q2 | 495.91 Million USD | -4.25% |
| 2013 FY | 517.91 Million USD | -10.91% |
| 2012 FY | 581.36 Million USD | 862.05% |
| 2012 Q1 | 581.36 Million USD | -3.26% |
| 2012 Q2 | 563.18 Million USD | -3.13% |
| 2012 Q3 | 485.53 Million USD | -13.79% |
| 2012 Q4 | 491.82 Million USD | 1.29% |
| 2011 Q4 | 600.97 Million USD | 1.1% |
| 2011 FY | 60.43 Million USD | -41.32% |
| 2011 Q1 | 60.43 Million USD | 18.21% |
| 2011 Q2 | 57.34 Million USD | -5.1% |
| 2011 Q3 | 594.42 Million USD | 936.54% |
| 2010 Q1 | 102.98 Million USD | 2.29% |
| 2010 FY | 102.98 Million USD | -21.74% |
| 2010 Q4 | 51.11 Million USD | 8.67% |
| 2010 Q3 | 47.04 Million USD | -46.66% |
| 2010 Q2 | 88.19 Million USD | -14.36% |
| 2009 Q1 | 131.59 Million USD | -10.54% |
| 2009 Q2 | 108.34 Million USD | -17.67% |
| 2009 Q3 | 105.24 Million USD | -2.86% |
| 2009 FY | 131.59 Million USD | -62.51% |
| 2009 Q4 | 100.67 Million USD | -4.34% |
| 2008 Q1 | 350.99 Million USD | 1.49% |
| 2008 Q3 | 266.05 Million USD | -16.91% |
| 2008 Q4 | 147.09 Million USD | -44.71% |
| 2008 FY | 350.99 Million USD | -3.88% |
| 2008 Q2 | 320.21 Million USD | -8.77% |
| 2007 Q3 | 334.12 Million USD | -2.11% |
| 2007 FY | 365.16 Million USD | -17.75% |
| 2007 Q1 | 365.16 Million USD | -1.61% |
| 2007 Q4 | 345.83 Million USD | 3.51% |
| 2007 Q2 | 341.33 Million USD | -6.52% |
| 2006 Q3 | 377.61 Million USD | -4.06% |
| 2006 Q1 | 443.94 Million USD | -3.59% |
| 2006 Q2 | 393.59 Million USD | -11.34% |
| 2006 FY | 443.94 Million USD | 32.62% |
| 2006 Q4 | 371.13 Million USD | -1.71% |
| 2005 FY | 334.76 Million USD | 72.47% |
| 2005 Q2 | 496.52 Million USD | 48.32% |
| 2005 Q1 | 334.76 Million USD | 82.96% |
| 2005 Q3 | 484.37 Million USD | -2.45% |
| 2005 Q4 | 460.45 Million USD | -4.94% |
| 2004 Q1 | 194.09 Million USD | -1.89% |
| 2004 Q2 | 194.69 Million USD | 0.31% |
| 2004 Q3 | 187.56 Million USD | -3.66% |
| 2004 Q4 | 182.97 Million USD | -2.45% |
| 2004 FY | 194.09 Million USD | -25.56% |
| 2003 Q2 | 260.05 Million USD | -0.26% |
| 2003 Q4 | 197.84 Million USD | 1.66% |
| 2003 Q3 | 194.61 Million USD | -25.16% |
| 2003 Q1 | 260.74 Million USD | 12.01% |
| 2003 FY | 260.74 Million USD | 4.01% |
| 2002 Q4 | 232.78 Million USD | -2.07% |
| 2002 Q3 | 237.69 Million USD | -2.23% |
| 2002 Q2 | 243.11 Million USD | -3.02% |
| 2002 Q1 | 250.68 Million USD | -5.47% |
| 2002 FY | 250.68 Million USD | 3.21% |
| 2001 FY | 242.88 Million USD | -1.26% |
| 2001 Q1 | 242.88 Million USD | 0.26% |
| 2001 Q4 | 265.18 Million USD | 10.21% |
| 2001 Q3 | 240.62 Million USD | -0.94% |
| 2001 Q2 | 242.91 Million USD | 0.01% |
| 2000 Q4 | 242.25 Million USD | -1.16% |
| 2000 FY | 245.99 Million USD | 329.88% |
| 2000 Q3 | 245.09 Million USD | -0.99% |
| 2000 Q1 | 245.99 Million USD | 390.04% |
| 2000 Q2 | 247.55 Million USD | 0.63% |
| 1999 FY | 57.22 Million USD | 48.36% |
| 1999 Q2 | 51.71 Million USD | -9.62% |
| 1999 Q3 | 51.4 Million USD | -0.61% |
| 1999 Q1 | 57.22 Million USD | 6.3% |
| 1999 Q4 | 50.19 Million USD | -2.34% |
| 1998 FY | 38.57 Million USD | 50.99% |
| 1998 Q1 | 38.57 Million USD | 18.71% |
| 1998 Q3 | 50.93 Million USD | 35.55% |
| 1998 Q4 | 53.82 Million USD | 5.68% |
| 1998 Q2 | 37.58 Million USD | -2.57% |
| 1997 Q4 | 32.49 Million USD | -1.12% |
| 1997 FY | 25.54 Million USD | 14.55% |
| 1997 Q1 | 25.54 Million USD | 5.91% |
| 1997 Q2 | 25.73 Million USD | 0.74% |
| 1997 Q3 | 32.85 Million USD | 27.69% |
| 1996 FY | 22.3 Million USD | 43.87% |
| 1996 Q2 | 20.3 Million USD | -8.94% |
| 1996 Q3 | 24.95 Million USD | 22.92% |
| 1996 Q1 | 22.3 Million USD | 0.45% |
| 1996 Q4 | 24.12 Million USD | -3.36% |
| 1995 Q1 | 15.5 Million USD | 14.81% |
| 1995 FY | 15.5 Million USD | 7.64% |
| 1995 Q3 | 18.2 Million USD | 35.82% |
| 1995 Q4 | 22.2 Million USD | 21.98% |
| 1995 Q2 | 13.4 Million USD | -13.55% |
| 1994 Q1 | 14.4 Million USD | 14.29% |
| 1994 Q2 | 12.3 Million USD | -14.58% |
| 1994 Q3 | 12.8 Million USD | 4.07% |
| 1994 Q4 | 13.5 Million USD | 5.47% |
| 1994 FY | 14.4 Million USD | 128.57% |
| 1993 Q2 | 4.8 Million USD | -23.81% |
| 1993 Q4 | 12.6 Million USD | 207.32% |
| 1993 Q1 | 6.3 Million USD | 53.66% |
| 1993 Q3 | 4.1 Million USD | -14.58% |
| 1993 FY | 6.3 Million USD | 320.0% |
| 1992 Q3 | 2 Million USD | -35.48% |
| 1992 FY | 1.5 Million USD | 0.0% |
| 1992 Q2 | 3.1 Million USD | 106.67% |
| 1992 Q1 | 1.5 Million USD | 0.0% |
| 1992 Q4 | 4.1 Million USD | 105.0% |
| 1991 Q3 | 1.2 Million USD | 71.43% |
| 1991 Q2 | 700 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Keros Therapeutics, Inc. | 37.81 Million USD | -2368.891% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 76.953% |
| Ligand Pharmaceuticals Incorporated | 130.7 Million USD | -614.221% |
| AlloVir, Inc. | 45.01 Million USD | -1973.835% |
| Precigen, Inc. | 41.64 Million USD | -2141.708% |
| Avidity Biosciences, Inc. | 127.79 Million USD | -630.519% |
| TransCode Therapeutics, Inc. | 3.52 Million USD | -26354.148% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -14028.918% |
| Sol-Gel Technologies Ltd. | 6.64 Million USD | -13952.943% |
| Acelyrin, Inc. | 86.35 Million USD | -981.071% |
| AbCellera Biologics Inc. | 335.77 Million USD | -178.024% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | -88.781% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | -2332.796% |
| Agenus Inc. | 462.29 Million USD | -101.935% |
| Dyadic International, Inc. | 2.34 Million USD | -39783.648% |
| Eton Pharmaceuticals, Inc. | 16.26 Million USD | -5640.251% |
| Lantern Pharma Inc. | 2.73 Million USD | -33974.648% |
| Immix Biopharma, Inc. | 3.72 Million USD | -24983.058% |
| IO Biotech, Inc. | 17.55 Million USD | -5217.481% |
| Outlook Therapeutics, Inc. | 46.73 Million USD | -1897.341% |
| Syros Pharmaceuticals, Inc. | 151.51 Million USD | -516.147% |
| Barinthus Biotherapeutics plc | 27.51 Million USD | -3293.323% |
| Aadi Bioscience, Inc. | 27.22 Million USD | -3328.592% |
| Akebia Therapeutics, Inc. | 272.28 Million USD | -242.85% |
| Aptorum Group Limited | 5.25 Million USD | -17658.865% |
| Ardelyx, Inc. | 130.76 Million USD | -613.915% |
| Arrowhead Pharmaceuticals, Inc. | 478.39 Million USD | -95.141% |
| Bicycle Therapeutics plc | 224.41 Million USD | -315.992% |
| BioXcel Therapeutics, Inc. | 130.21 Million USD | -616.947% |
| Chimerix, Inc. | 19.74 Million USD | -4627.967% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -2553.819% |
| CRISPR Therapeutics AG | 346.76 Million USD | -169.211% |
| Elevation Oncology, Inc. | 34.28 Million USD | -2623.111% |
| ESSA Pharma Inc. | 3.49 Million USD | -26610.101% |
| Fortress Biotech, Inc. | 165.93 Million USD | -462.578% |
| Fortress Biotech, Inc. | 165.93 Million USD | -462.578% |
| NextCure, Inc. | 14.99 Million USD | -6124.825% |
| Ocuphire Pharma, Inc. | 4.04 Million USD | -22995.918% |
| Onconetix, Inc. | 23.18 Million USD | -3927.184% |
| Opthea Limited | 264.6 Million USD | -252.809% |
| PDS Biotechnology Corporation | 33.25 Million USD | -2706.859% |
| GT Biopharma, Inc. | 6.63 Million USD | -13974.129% |
| HOOKIPA Pharma Inc. | 71.48 Million USD | -1206.011% |
| ImmuCell Corporation | 18.81 Million USD | -4861.657% |
| IDEAYA Biosciences, Inc. | 28.22 Million USD | -3207.366% |
| Inhibikase Therapeutics, Inc. | 3.52 Million USD | -26355.363% |
| Incyte Corporation | 1.59 Billion USD | 41.371% |
| Jaguar Health, Inc. | 45.86 Million USD | -1935.357% |
| Janux Therapeutics, Inc. | 36.05 Million USD | -2488.987% |
| Kintara Therapeutics, Inc. | 2.44 Million USD | -38081.472% |
| Longboard Pharmaceuticals, Inc. | 9.77 Million USD | -9451.228% |
| ContextLogic Inc. | 206 Million USD | -353.173% |
| Madrigal Pharmaceuticals, Inc. | 235.21 Million USD | -296.888% |
| MiMedx Group, Inc. | 96.33 Million USD | -869.103% |
| MEI Pharma, Inc. | 8.35 Million USD | -11073.393% |
| Pyxis Oncology, Inc. | 48.02 Million USD | -1843.978% |
| Seer, Inc. | 39.36 Million USD | -2271.49% |
| Salarius Pharmaceuticals, Inc. | 1.29 Million USD | -71752.489% |
| Novavax, Inc. | 2.57 Billion USD | 63.708% |
| Clearside Biomedical, Inc. | 49.93 Million USD | -1769.692% |
| Oncternal Therapeutics, Inc. | 6.67 Million USD | -13881.384% |
| VYNE Therapeutics Inc. | 8.95 Million USD | -10330.581% |
| Wave Life Sciences Ltd. | 227.44 Million USD | -310.445% |
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | -168.582% |
| Psyence Biomedical Ltd. | 12.1 Million USD | -7612.187% |
| Vaxcyte, Inc. | 167.44 Million USD | -457.505% |
| C4 Therapeutics, Inc. | 130.33 Million USD | -616.249% |
| Pharming Group N.V. | 244.07 Million USD | -282.483% |
| Phathom Pharmaceuticals, Inc. | 486.6 Million USD | -91.849% |
| Pieris Pharmaceuticals, Inc. | 11.92 Million USD | -7730.372% |
| PureTech Health plc | 125.58 Million USD | -643.363% |
| Rigel Pharmaceuticals, Inc. | 145.86 Million USD | -539.983% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -14028.918% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -1032.48% |
| SELLAS Life Sciences Group, Inc. | 14.37 Million USD | -6392.364% |
| Sensei Biotherapeutics, Inc. | 9.47 Million USD | -9748.476% |
| Senti Biosciences, Inc. | 52.57 Million USD | -1675.764% |
| Stoke Therapeutics, Inc. | 68.77 Million USD | -1257.339% |
| Alaunos Therapeutics, Inc. | 1.95 Million USD | -47626.84% |
| Telomir Pharmaceuticals, Inc. Common Stock | 1.33 Million USD | -69798.335% |
| Entrada Therapeutics, Inc. | 226.83 Million USD | -311.554% |
| Verrica Pharmaceuticals Inc. | 61.83 Million USD | -1409.747% |
| VistaGen Therapeutics, Inc. | 9.36 Million USD | -9866.233% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -3117.429% |
| ChromaDex Corporation | 26.5 Million USD | -3421.718% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -8453.573% |
| Caribou Biosciences, Inc. | 72.56 Million USD | -1186.448% |
| Precision BioSciences, Inc. | 140.92 Million USD | -562.459% |
| Fate Therapeutics, Inc. | 137.8 Million USD | -577.458% |
| Innoviva, Inc. | 568.55 Million USD | -64.196% |
| Summit Therapeutics Inc. | 125.25 Million USD | -645.297% |
| GlycoMimetics, Inc. | 6.9 Million USD | -13425.456% |
| Inhibrx Biosciences, Inc. | 264.39 Million USD | -253.091% |
| Catalyst Pharmaceuticals, Inc. | 84.02 Million USD | -1011.01% |
| Orchestra BioMed Holdings, Inc. | 27.16 Million USD | -3336.037% |
| Alzamend Neuro, Inc. | 3.22 Million USD | -28839.947% |
| Rocket Pharmaceuticals, Inc. | 73.76 Million USD | -1165.521% |
| Aptose Biosciences Inc. | 15.8 Million USD | -5805.21% |
| ZyVersa Therapeutics, Inc. | 11.03 Million USD | -8356.192% |
| Soligenix, Inc. | 7.27 Million USD | -12732.293% |
| Century Therapeutics, Inc. | 175.94 Million USD | -430.597% |
| Kura Oncology, Inc. | 51.66 Million USD | -1707.009% |
| TScan Therapeutics, Inc. | 121.28 Million USD | -669.724% |
| Intensity Therapeutics, Inc. | 4.13 Million USD | -22487.394% |
| Ocean Biomedical, Inc. | 6.61 Million USD | -14014.869% |
| CytomX Therapeutics, Inc. | 252.59 Million USD | -269.574% |
| Autolus Therapeutics plc | 263.9 Million USD | -253.737% |
| Mineralys Therapeutics, Inc. | 10.48 Million USD | -8806.096% |
| EyePoint Pharmaceuticals, Inc. | 88.86 Million USD | -950.559% |
| Eterna Therapeutics Inc. | 46.89 Million USD | -1890.526% |
| Adaptive Biotechnologies Corporation | 352.85 Million USD | -164.566% |
| GRI Bio, Inc. | 2.69 Million USD | -34513.904% |
| Xenetic Biosciences, Inc. | 809.58 Thousand USD | -115210.56% |
| Tenaya Therapeutics, Inc. | 31.09 Million USD | -2902.596% |
| IGM Biosciences, Inc. | 220.17 Million USD | -323.994% |
| INmune Bio, Inc. | 18.86 Million USD | -4849.3% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -263.982% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -3404.03% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -34241.338% |
| Entero Therapeutics, Inc. | 3.28 Million USD | -28359.186% |
| Milestone Pharmaceuticals Inc. | 58.45 Million USD | -1497.018% |
| X4 Pharmaceuticals, Inc. | 96.15 Million USD | -870.826% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -252.631% |
| Coherus BioSciences, Inc. | 823.02 Million USD | -13.427% |
| Verastem, Inc. | 71.18 Million USD | -1211.424% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -1798.359% |
| Pliant Therapeutics, Inc. | 38.57 Million USD | -2319.869% |
| Tonix Pharmaceuticals Holding Corp. | 48.93 Million USD | -1807.825% |
| Histogen Inc. | 5.69 Million USD | -16286.467% |
| Aprea Therapeutics, Inc. | 4.38 Million USD | -21186.39% |
| Surrozen, Inc. | 8.14 Million USD | -11361.473% |
| Organovo Holdings, Inc. | 2.74 Million USD | -33871.507% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -297339.288% |
| Ovid Therapeutics Inc. | 56.22 Million USD | -1560.215% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -5553.688% |
| CASI Pharmaceuticals, Inc. | 51.1 Million USD | -1726.775% |
| Cadrenal Therapeutics, Inc. Common Stock | 826.87 Thousand USD | -112799.41% |
| Centessa Pharmaceuticals plc | 126.72 Million USD | -636.664% |
| Hepion Pharmaceuticals, Inc. | 10.81 Million USD | -8532.998% |
| Arcturus Therapeutics Holdings Inc. | 150.88 Million USD | -518.691% |
| BioRestorative Therapies, Inc. | 2.6 Million USD | -35704.123% |
| Apollomics, Inc. | 14.15 Million USD | -6496.036% |
| Amarin Corporation plc | 279.58 Million USD | -233.899% |
| Mesoblast Limited | 188.79 Million USD | -394.463% |
| Turnstone Biologics Corp. | 14.14 Million USD | -6498.367% |
| Kymera Therapeutics, Inc. | 180.78 Million USD | -416.371% |
| Synaptogenix, Inc. | 5.52 Million USD | -16782.941% |
| Tiziana Life Sciences Ltd | 6.64 Million USD | -13942.374% |
| Aurinia Pharmaceuticals Inc. | 170.1 Million USD | -448.791% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -10809.383% |
| Monopar Therapeutics Inc. | 1.75 Million USD | -53020.56% |
| Exelixis, Inc. | 678.44 Million USD | -37.6% |
| Better Therapeutics, Inc. | 23.84 Million USD | -3815.515% |
| Nurix Therapeutics, Inc. | 164.04 Million USD | -469.07% |
| Apellis Pharmaceuticals, Inc. | 594.2 Million USD | -57.106% |
| NLS Pharmaceutics AG | 10.68 Million USD | -8640.816% |
| Dermata Therapeutics, Inc. | 1.62 Million USD | -57397.401% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | -2298.174% |
| Gritstone bio, Inc. | 125.91 Million USD | -641.379% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -6260.977% |
| TNF Pharmaceuticals, Inc. | 5.08 Million USD | -18245.558% |
| Avid Bioservices, Inc. | 275.66 Million USD | -238.645% |
| Insmed Incorporated | 1.66 Billion USD | 43.822% |
| Virpax Pharmaceuticals, Inc. | 7.69 Million USD | -12033.274% |
| MediWound Ltd. | 27.18 Million USD | -3333.762% |
| OmniAb, Inc. | 87.4 Million USD | -968.12% |
| Alector, Inc. | 487.66 Million USD | -91.428% |
| Seres Therapeutics, Inc. | 403.45 Million USD | -131.385% |
| Checkpoint Therapeutics, Inc. | 18.42 Million USD | -4966.687% |
| Zai Lab Limited | 240.17 Million USD | -288.687% |
| Revance Therapeutics, Inc. | 630.05 Million USD | -48.167% |
| Aura Biosciences, Inc. | 29.22 Million USD | -3094.091% |
| Lyell Immunopharma, Inc. | 95.07 Million USD | -881.875% |
| Immunic, Inc. | 25.36 Million USD | -3579.979% |
| Tarsus Pharmaceuticals, Inc. | 69.23 Million USD | -1248.34% |
| Veracyte, Inc. | 93.71 Million USD | -896.102% |
| InMed Pharmaceuticals Inc. | 2.61 Million USD | -35576.487% |
| FibroGen, Inc. | 585.72 Million USD | -59.381% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -5270.402% |
| Adial Pharmaceuticals, Inc. | 653.07 Thousand USD | -142844.619% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.65 Million USD | -16406.833% |
| Jazz Pharmaceuticals plc | 7.65 Billion USD | 87.807% |
| Cyclacel Pharmaceuticals, Inc. | 8.19 Million USD | -11287.375% |
| Amylyx Pharmaceuticals, Inc. | 84.02 Million USD | -1011.063% |
| TG Therapeutics, Inc. | 169.08 Million USD | -452.111% |
| Galecto, Inc. | 5.89 Million USD | -15733.396% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -11169.157% |
| Fortrea Holdings Inc. | 2.61 Billion USD | 64.347% |
| KalVista Pharmaceuticals, Inc. | 28.82 Million USD | -3138.974% |
| Aptevo Therapeutics Inc. | 12.62 Million USD | -7296.696% |
| XBiotech Inc. | 8.39 Million USD | -11017.506% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -6260.977% |
| Lyra Therapeutics, Inc. | 53.18 Million USD | -1655.429% |
| Foghorn Therapeutics Inc. | 363.1 Million USD | -157.098% |
| Y-mAbs Therapeutics, Inc. | 26.88 Million USD | -3372.463% |
| Theravance Biopharma, Inc. | 169 Million USD | -452.376% |
| Ultragenyx Pharmaceutical Inc. | 1.21 Billion USD | 23.204% |
| Metagenomi, Inc. Common Stock | 500.42 Million USD | -86.548% |
| Vaxxinity, Inc. | 30.94 Million USD | -2916.859% |
| BioCryst Pharmaceuticals, Inc. | 972.48 Million USD | 4.005% |
| Gain Therapeutics, Inc. | 6.03 Million USD | -15378.701% |
| Cartesian Therapeutics, Inc. | 745.23 Million USD | -25.268% |
| NexImmune, Inc. | 5.08 Million USD | -18261.416% |
| Creative Medical Technology Holdings, Inc. | 371.39 Thousand USD | -251260.28% |
| Marker Therapeutics, Inc. | 3.07 Million USD | -30260.428% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 86.865% |
| Chemomab Therapeutics Ltd. | 5.15 Million USD | -18012.758% |
| Scopus BioPharma Inc. | 7.45 Million USD | -12423.245% |
| RAPT Therapeutics, Inc. | 26.29 Million USD | -3450.38% |
| Ainos, Inc. | 7.39 Million USD | -12525.221% |
| Pluri Inc. | 34.11 Million USD | -2636.682% |
| Prothena Corporation plc | 135.01 Million USD | -591.422% |
| Adaptimmune Therapeutics plc | 243.1 Million USD | -284.009% |
| Celularity Inc. | 102.92 Million USD | -806.972% |
| Rallybio Corporation | 9.43 Million USD | -9793.355% |
| Cue Biopharma, Inc. | 24.44 Million USD | -3718.928% |
| MeiraGTx Holdings plc | 319.99 Million USD | -191.739% |
| Omeros Corporation | 403.25 Million USD | -131.502% |
| Humacyte, Inc. | 114.67 Million USD | -714.058% |
| Immunocore Holdings plc | 228.15 Million USD | -309.163% |
| Cocrystal Pharma, Inc. | 4.87 Million USD | -19049.477% |
| Cidara Therapeutics, Inc. | 76.74 Million USD | -1116.493% |
| Blueprint Medicines Corporation | 918.64 Million USD | -1.622% |
| CalciMedica, Inc. | 4.02 Million USD | -23076.192% |
| Cabaletta Bio, Inc. | 17.45 Million USD | -5249.169% |
| Marinus Pharmaceuticals, Inc. | 154.14 Million USD | -505.63% |
| Scholar Rock Holding Corporation | 85.81 Million USD | -987.823% |
| Sana Biotechnology, Inc. | 277.79 Million USD | -236.055% |
| Pulmatrix, Inc. | 15.96 Million USD | -5748.13% |
| Elicio Therapeutics, Inc. | 15.77 Million USD | -5818.576% |
| Vigil Neuroscience, Inc. | 24.6 Million USD | -3693.941% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -272.212% |
| Adlai Nortye Ltd. American Depositary Shares | 50.78 Million USD | -1738.177% |
| Cytokinetics, Incorporated | 1.21 Billion USD | 22.889% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | -2837.221% |
| Nutriband Inc. | 1.07 Million USD | -86425.216% |
| Protara Therapeutics, Inc. | 10.63 Million USD | -8679.62% |
| Vor Biopharma Inc. | 59.1 Million USD | -1479.482% |
| Roivant Sciences Ltd. | 773.95 Million USD | -20.619% |
| Evogene Ltd. | 17.99 Million USD | -5089.2% |
| ProKidney Corp. | 29.21 Million USD | -3095.294% |
| Applied Therapeutics, Inc. | 71.97 Million USD | -1196.957% |
| Hoth Therapeutics, Inc. | 704.98 Thousand USD | -132319.789% |
| BridgeBio Pharma, Inc. | 1.88 Billion USD | 50.578% |
| CorMedix Inc. | 11.91 Million USD | -7733.311% |
| BioLineRx Ltd. | 50.7 Million USD | -1741.223% |
| Tango Therapeutics, Inc. | 149.45 Million USD | -524.611% |
| Galectin Therapeutics Inc. | 88.44 Million USD | -955.548% |
| Atai Life Sciences N.V. | 49.16 Million USD | -1798.9% |
| Renovaro Biosciences Inc. | 31.15 Million USD | -2896.687% |
| Aerovate Therapeutics, Inc. | 17.96 Million USD | -5097.289% |
| Zentalis Pharmaceuticals, Inc. | 124.63 Million USD | -649.011% |
| Sagimet Biosciences Inc. | 5.65 Million USD | -16411.089% |
| MediciNova, Inc. | 3.89 Million USD | -23888.803% |
| Praxis Precision Medicines, Inc. | 18.27 Million USD | -5007.156% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -61960.335% |
| GeoVax Labs, Inc. | 3.51 Million USD | -26421.834% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -134.995% |
| Biomea Fusion, Inc. | 30.69 Million USD | -2941.828% |
| PTC Therapeutics, Inc. | 2.72 Billion USD | 65.701% |
| Mereo BioPharma Group plc | 15.96 Million USD | -5748.496% |
| Cullinan Oncology, Inc. | 31.2 Million USD | -2892.01% |
| Syndax Pharmaceuticals, Inc. | 58.68 Million USD | -1490.786% |
| Absci Corporation | 58.3 Million USD | -1501.154% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -4800.971% |
| 4D Molecular Therapeutics, Inc. | 32.06 Million USD | -2811.662% |
| Dyne Therapeutics, Inc. | 73.79 Million USD | -1165.127% |
| Kiniksa Pharmaceuticals, Ltd. | 87.48 Million USD | -967.107% |
| Ventyx Biosciences, Inc. | 33.77 Million USD | -2664.397% |
| Allakos Inc. | 74.79 Million USD | -1148.161% |
| Imunon, Inc. | 8.53 Million USD | -10843.614% |
| Fulcrum Therapeutics, Inc. | 22.5 Million USD | -4048.869% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -713.101% |
| BioAtla, Inc. | 48.98 Million USD | -1805.722% |
| NLS Pharmaceutics AG | 10.68 Million USD | -8640.816% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -33492.551% |
| Allogene Therapeutics, Inc. | 130.6 Million USD | -614.784% |
| Larimar Therapeutics, Inc. | 14.21 Million USD | -6467.267% |
| XOMA Corporation | 145.58 Million USD | -541.254% |
| Kezar Life Sciences, Inc. | 33.66 Million USD | -2673.019% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -1257.694% |
| aTyr Pharma, Inc. | 31.59 Million USD | -2854.512% |
| Aligos Therapeutics, Inc. | 61.82 Million USD | -1410.016% |
| Akero Therapeutics, Inc. | 44.96 Million USD | -1976.141% |
| Viridian Therapeutics, Inc. | 48.4 Million USD | -1828.716% |
| Eliem Therapeutics, Inc. | 2.87 Million USD | -32427.422% |
| EyeGate Pharmaceuticals, Inc. | 8.15 Million USD | -11343.184% |
| Akari Therapeutics, Plc | 4.58 Million USD | -20265.118% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -5164.367% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 43.404% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -231026.148% |
| UroGen Pharma Ltd. | 243.52 Million USD | -283.347% |
| Sutro Biopharma, Inc. | 321.08 Million USD | -190.743% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -33704.722% |
| Orgenesis Inc. | 35.53 Million USD | -2527.092% |
| Entera Bio Ltd. | 1.37 Million USD | -67596.664% |
| GH Research PLC | 6.7 Million USD | -13831.309% |
| Lisata Therapeutics, Inc. | 6.8 Million USD | -13628.485% |
| Reneo Pharmaceuticals, Inc. | 18.82 Million USD | -4858.764% |
| Xencor, Inc. | 283.55 Million USD | -229.221% |
| 60 Degrees Pharmaceuticals, Inc. | 2.98 Million USD | -31167.201% |
| Replimune Group, Inc. | 113.21 Million USD | -724.577% |
| Coeptis Therapeutics Holdings, Inc. | 3.75 Million USD | -24747.11% |
| Vanda Pharmaceuticals Inc. | 103.53 Million USD | -801.707% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -231026.148% |
| Portage Biotech Inc. | 4.45 Million USD | -20878.36% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -61960.335% |
| Olema Pharmaceuticals, Inc. | 23.05 Million USD | -3950.052% |
| OncoCyte Corporation | 49.29 Million USD | -1793.661% |
| Qualigen Therapeutics, Inc. | 4.13 Million USD | -22466.618% |
| Processa Pharmaceuticals, Inc. | 797.48 Thousand USD | -116960.28% |
| Purple Biotech Ltd. | 10 Million USD | -9230.705% |
| CollPlant Biotechnologies Ltd. | 5.78 Million USD | -16034.411% |
| scPharmaceuticals Inc. | 57.26 Million USD | -1530.319% |
| ProMIS Neurosciences, Inc. | 12.38 Million USD | -7435.804% |
| HilleVax, Inc. | 78.9 Million USD | -1083.055% |
| NeuroSense Therapeutics Ltd. | 5.05 Million USD | -18385.881% |
| Tharimmune, Inc. | 1.81 Million USD | -51333.242% |
| Genprex, Inc. | 3.25 Million USD | -28587.072% |
| Neumora Therapeutics, Inc. Common Stock | 27.11 Million USD | -3342.373% |
| Atossa Therapeutics, Inc. | 5.23 Million USD | -17729.202% |
| XTL Biopharmaceuticals Ltd. | 206 Thousand USD | -453073.301% |
| Virios Therapeutics, Inc. | 358.54 Thousand USD | -260265.976% |
| OKYO Pharma Limited | 7.42 Million USD | -12479.927% |
| Savara Inc. | 37.19 Million USD | -2410.048% |
| Curis, Inc. | 57.61 Million USD | -1520.386% |
| Daré Bioscience, Inc. | 26.32 Million USD | -3445.546% |
| Carmell Therapeutics Corporation | 39.19 Million USD | -2281.485% |
| Titan Pharmaceuticals, Inc. | 1.44 Million USD | -64549.377% |
| Achieve Life Sciences, Inc. | 20.81 Million USD | -4384.063% |
| BeiGene, Ltd. | 2.23 Billion USD | 58.208% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -4284.903% |
| Revolution Medicines, Inc. Warrant | 262.39 Million USD | -255.773% |
| Protagonist Therapeutics, Inc. | 21.27 Million USD | -4288.159% |
| Erasca, Inc. | 78.61 Million USD | -1087.54% |
| bluebird bio, Inc. | 424.62 Million USD | -119.85% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -142369.92% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 50.608% |
| DBV Technologies S.A. | 42.8 Million USD | -2081.161% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -142369.92% |
| Moderna, Inc. | 4.57 Billion USD | 79.581% |
| Vincerx Pharma, Inc. | 6.99 Million USD | -13245.776% |
| Fresh Tracks Therapeutics, Inc. | 1.65 Million USD | -56273.007% |
| Molecular Templates, Inc. | 31.17 Million USD | -2894.889% |
| Acrivon Therapeutics, Inc. Common Stock | 17.07 Million USD | -5368.875% |
| Travere Therapeutics, Inc. | 588.1 Million USD | -58.737% |
| Monte Rosa Therapeutics, Inc. | 124.5 Million USD | -649.799% |
| Spruce Biosciences, Inc. | 27.43 Million USD | -3302.475% |
| Celldex Therapeutics, Inc. | 36.45 Million USD | -2460.723% |
| Cogent Biosciences, Inc. | 55.63 Million USD | -1577.967% |
| MacroGenics, Inc. | 154.2 Million USD | -505.379% |
| RenovoRx, Inc. | 4.46 Million USD | -20803.202% |
| Adicet Bio, Inc. | 37.12 Million USD | -2414.916% |
| Prime Medicine, Inc. | 60.78 Million USD | -1435.928% |
| Aditxt, Inc. | 28.53 Million USD | -3171.945% |
| Adagene Inc. | 45.16 Million USD | -1966.749% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -516519.72% |
| Quantum-Si incorporated | 26.63 Million USD | -3405.452% |
| Maravai LifeSciences Holdings, Inc. | 697.56 Million USD | -33.828% |
| Acurx Pharmaceuticals, Inc. | 3.04 Million USD | -30583.846% |
| Voyager Therapeutics, Inc. | 114.96 Million USD | -712.047% |
| SciSparc Ltd. | 1.59 Million USD | -58428.966% |
| Vericel Corporation | 127.7 Million USD | -631.011% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -16675.468% |
| Minerva Neurosciences, Inc. | 85.35 Million USD | -993.671% |
| Generation Bio Co. | 171.63 Million USD | -443.924% |
| Astria Therapeutics, Inc. | 11.55 Million USD | -7982.571% |
| Black Diamond Therapeutics, Inc. | 41.83 Million USD | -2131.687% |
| Arcutis Biotherapeutics, Inc. | 252.69 Million USD | -269.428% |
| Invivyd, Inc. | 51.71 Million USD | -1705.227% |
| Relay Therapeutics, Inc. | 91.97 Million USD | -914.968% |
| Quoin Pharmaceuticals, Ltd. | 6.5 Million USD | -14250.515% |
| Spero Therapeutics, Inc. | 75.49 Million USD | -1136.538% |
| Artelo Biosciences, Inc. | 1.02 Million USD | -91333.595% |
| 2seventy bio, Inc. | 310.12 Million USD | -201.019% |
| ADMA Biologics, Inc. | 193.97 Million USD | -381.264% |
| Clene Inc. | 38.95 Million USD | -2296.696% |
| Capricor Therapeutics, Inc. | 36.13 Million USD | -2483.623% |
| Boundless Bio, Inc. Common Stock | 256.97 Million USD | -263.278% |
| GeoVax Labs, Inc. | 3.51 Million USD | -26421.834% |
| Recursion Pharmaceuticals, Inc. | 190.26 Million USD | -390.656% |
| Citius Pharmaceuticals, Inc. | 12.17 Million USD | -7564.72% |
| Contineum Therapeutics, Inc. Class A Common Stock | 198.32 Million USD | -370.718% |
| Relmada Therapeutics, Inc. | 12.19 Million USD | -7555.205% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | -1840.382% |
| ALX Oncology Holdings Inc. | 52.84 Million USD | -1666.691% |
| Vir Biotechnology, Inc. | 369.85 Million USD | -152.407% |
| Evaxion Biotech A/S | 17.61 Million USD | -5198.925% |
| Ocular Therapeutix, Inc. | 160.92 Million USD | -480.092% |
| Verve Therapeutics, Inc. | 153.18 Million USD | -509.414% |
| Trevena, Inc. | 48.26 Million USD | -1834.311% |
| Surrozen, Inc. | 8.14 Million USD | -11361.473% |
| Tyra Biosciences, Inc. | 21.59 Million USD | -4222.931% |
| Cingulate Inc. | 10.36 Million USD | -8910.223% |
| Galmed Pharmaceuticals Ltd. | 2.75 Million USD | -33846.8% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -2403.317% |
| Tenax Therapeutics, Inc. | 3.58 Million USD | -25929.048% |
| Terns Pharmaceuticals, Inc. | 13.15 Million USD | -6999.141% |
| ACADIA Pharmaceuticals Inc. | 317.2 Million USD | -194.305% |
| Connect Biopharma Holdings Limited | 24.84 Million USD | -3656.839% |
| Clearmind Medicine Inc. | 3.61 Million USD | -25759.693% |
| Kronos Bio, Inc. | 54.2 Million USD | -1622.361% |
| Bolt Biotherapeutics, Inc. | 47.04 Million USD | -1884.433% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -4001.705% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -4551.173% |
| Statera Biopharma, Inc. | 22.67 Million USD | -4016.768% |
| ImmunityBio, Inc. | 1.09 Billion USD | 14.385% |
| Korro Bio, Inc. | 51.75 Million USD | -1703.867% |
| Kineta, Inc. | 7.22 Million USD | -12826.295% |
| BioVie Inc. | 9.7 Million USD | -9521.98% |
| Codexis, Inc. | 49.94 Million USD | -1769.093% |
| Celularity Inc. | 102.92 Million USD | -806.972% |
| Crinetics Pharmaceuticals, Inc. | 96.24 Million USD | -869.939% |
| Celcuity Inc. | 51.45 Million USD | -1714.452% |
| Virax Biolabs Group Limited | 345.19 Thousand USD | -270338.362% |
| Cibus, Inc. | 206.11 Million USD | -352.916% |
| Eledon Pharmaceuticals, Inc. | 42.47 Million USD | -2097.851% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -3444.315% |
| IN8bio, Inc. | 8.77 Million USD | -10542.237% |
| Kodiak Sciences Inc. | 213.59 Million USD | -337.068% |
| Annexon, Inc. | 47.11 Million USD | -1881.275% |
| Adverum Biotechnologies, Inc. | 89.54 Million USD | -942.58% |
| Assembly Biosciences, Inc. | 96.37 Million USD | -868.681% |
| Avalo Therapeutics, Inc. | 13.68 Million USD | -6719.614% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 64.141% |
| Eyenovia, Inc. | 19.78 Million USD | -4619.534% |
| Puma Biotechnology, Inc. | 177.08 Million USD | -427.166% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -12053.847% |
| Xilio Therapeutics, Inc. | 24.09 Million USD | -3773.758% |
| Arcellx, Inc. | 339.75 Million USD | -174.77% |
| Cardiff Oncology, Inc. | 11.89 Million USD | -7746.167% |
| Enanta Pharmaceuticals, Inc. | 245.54 Million USD | -280.198% |
| Regulus Therapeutics Inc. | 9.56 Million USD | -9661.968% |
| Moolec Science SA | 13.94 Million USD | -6594.25% |
| Acumen Pharmaceuticals, Inc. | 43.15 Million USD | -2063.369% |
| Geron Corporation | 146.12 Million USD | -538.853% |
| LAVA Therapeutics N.V. | 50.53 Million USD | -1747.417% |
| Royalty Pharma plc | 6.29 Billion USD | 85.176% |
| Atea Pharmaceuticals, Inc. | 39.77 Million USD | -2246.986% |
| Greenwich LifeSciences, Inc. | 294.4 Thousand USD | -316991.703% |
| TFF Pharmaceuticals, Inc. | 2.46 Million USD | -37844.309% |
| Mersana Therapeutics, Inc. | 189.15 Million USD | -393.528% |
| Humacyte, Inc. | 114.67 Million USD | -714.058% |
| Structure Therapeutics Inc. | 29.05 Million USD | -3113.441% |
| 89bio, Inc. | 59.96 Million USD | -1456.855% |
| PMV Pharmaceuticals, Inc. | 26.46 Million USD | -3427.707% |
| Avenue Therapeutics, Inc. | 1.19 Million USD | -77954.933% |
| Genelux Corporation | 8.42 Million USD | -10987.138% |
| Trevi Therapeutics, Inc. | 6.85 Million USD | -13516.351% |
| Lexicon Pharmaceuticals, Inc. | 136.31 Million USD | -584.818% |
| Notable Labs, Ltd. | 4.42 Million USD | -20987.35% |
| Liquidia Corporation | 73.13 Million USD | -1176.405% |
| Mustang Bio, Inc. | 17.61 Million USD | -5198.468% |
| Immunovant, Inc. | 48.95 Million USD | -1806.929% |
| Quantum-Si incorporated | 26.63 Million USD | -3405.452% |
| Arbutus Biopharma Corporation | 38.38 Million USD | -2332.163% |
| DiaMedica Therapeutics Inc. | 3.1 Million USD | -29984.982% |
| Vera Therapeutics, Inc. | 73.86 Million USD | -1163.911% |
| Acasti Pharma Inc. | 11.55 Million USD | -7977.676% |
| MiNK Therapeutics, Inc. | 22.6 Million USD | -4029.282% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -34241.338% |
| Xenon Pharmaceuticals Inc. | 36.87 Million USD | -2431.488% |
| Elevai Labs, Inc. Common Stock | 1.36 Million USD | -68399.283% |
| NeuroBo Pharmaceuticals, Inc. | 6.09 Million USD | -15213.927% |
| Tempest Therapeutics, Inc. | 24.83 Million USD | -3658.957% |
| Soleno Therapeutics, Inc. | 23.18 Million USD | -3926.643% |
| PepGen Inc. | 34.63 Million USD | -2595.669% |
| Moleculin Biotech, Inc. | 12.14 Million USD | -7587.228% |
| United Therapeutics Corporation | 1.18 Billion USD | 21.034% |
| Nuvectis Pharma, Inc. | 6.98 Million USD | -13266.796% |
| Solid Biosciences Inc. | 38.45 Million USD | -2327.42% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -10809.383% |
| Immuneering Corporation | 12 Million USD | -7674.062% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -297339.288% |
| Silo Pharma, Inc. | 1.56 Million USD | -59388.616% |
| Belite Bio, Inc | 4.21 Million USD | -22069.01% |
| XOMA Corporation | 145.58 Million USD | -541.254% |
| ARS Pharmaceuticals, Inc. | 2.42 Million USD | -38348.806% |
| Bionomics Limited | 10.15 Million USD | -9089.513% |
| Apogee Therapeutics, Inc. | 21.49 Million USD | -4243.851% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -3974.268% |
| uniQure N.V. | 624.01 Million USD | -49.601% |
| Cassava Sciences, Inc. | 14.19 Million USD | -6476.52% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -516519.72% |
| Poseida Therapeutics, Inc. | 170.18 Million USD | -448.546% |
| Forte Biosciences, Inc. | 3.66 Million USD | -25364.73% |
| Anebulo Pharmaceuticals, Inc. | 260.58 Thousand USD | -358149.387% |
| Enlivex Therapeutics Ltd. | 6.74 Million USD | -13736.327% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -12053.847% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -5270.402% |
| FibroBiologics, Inc. Common Stock | 10.56 Million USD | -8733.62% |
| Altimmune, Inc. | 16.54 Million USD | -5543.776% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | -51.13% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -3974.268% |
| Compugen Ltd. | 55.77 Million USD | -1573.755% |
| Peak Bio, Inc. | 20.75 Million USD | -4398.244% |
| Zevra Therapeutics, Inc. | 110.46 Million USD | -745.113% |
| Benitec Biopharma Inc. | 4.96 Million USD | -18713.724% |
| Spyre Therapeutics, Inc. | 157.84 Million USD | -491.434% |
| NKGen Biotech, Inc. Common Stock | 75.17 Million USD | -1141.835% |
| Zura Bio Limited | 21.29 Million USD | -4284.45% |
| PolyPid Ltd. | 17.46 Million USD | -5244.27% |
| Aileron Therapeutics, Inc. | 112.39 Million USD | -730.556% |
| NKGen Biotech, Inc. Warrants | 75.17 Million USD | -1141.835% |
| Instil Bio, Inc. | 99.8 Million USD | -835.398% |
| argenx SE | 444.95 Million USD | -109.807% |
| Immunome, Inc. | 28.65 Million USD | -3157.509% |
| Compass Therapeutics, Inc. | 8.33 Million USD | -11097.517% |
| Verona Pharma plc | 58.84 Million USD | -1486.542% |
| enGene Holdings Inc. Warrants | 14.47 Million USD | -6350.197% |
| Shattuck Labs, Inc. | 14.85 Million USD | -6182.637% |
| CervoMed Inc. | 2.59 Million USD | -35864.098% |
| LENZ Therapeutics, Inc. | 4.87 Million USD | -19053.406% |
| Plus Therapeutics, Inc. | 12.73 Million USD | -7229.907% |
| Dianthus Therapeutics, Inc. | 10.53 Million USD | -8761.291% |
| Moolec Science SA | 13.94 Million USD | -6594.25% |
| Enveric Biosciences, Inc. | 2.34 Million USD | -39735.093% |
| Inovio Pharmaceuticals, Inc. | 55.59 Million USD | -1579.166% |
| AnaptysBio, Inc. | 364.28 Million USD | -156.265% |
| Design Therapeutics, Inc. | 11.95 Million USD | -7708.105% |
| Leap Therapeutics, Inc. | 12.68 Million USD | -7259.957% |
| NeurAxis, Inc. | 1.91 Million USD | -48706.293% |
| Seelos Therapeutics, Inc. | 38.92 Million USD | -2298.112% |
| Lumos Pharma, Inc. | 13.33 Million USD | -6901.703% |
| Achilles Therapeutics plc | 19.08 Million USD | -4790.957% |
| enGene Holdings Inc. Common Stock | 14.47 Million USD | -6350.197% |
| 180 Life Sciences Corp. | 5.38 Million USD | -17228.769% |
| Opiant Pharmaceuticals, Inc. | 23.58 Million USD | -3857.679% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -4001.705% |
| Nutriband Inc. | 1.07 Million USD | -86425.216% |
| ORIC Pharmaceuticals, Inc. | 30.59 Million USD | -2950.974% |
| CG Oncology, Inc. Common stock | 14.51 Million USD | -6333.306% |
| Fractyl Health, Inc. Common Stock | 401.27 Million USD | -132.643% |
| Rani Therapeutics Holdings, Inc. | 32.47 Million USD | -2774.81% |
| MoonLake Immunotherapeutics | 13.04 Million USD | -7054.036% |
| Palisade Bio, Inc. | 2.73 Million USD | -33983.133% |
| Tourmaline Bio, Inc. | 5.25 Million USD | -17671.502% |
| Beam Therapeutics Inc. | 478.38 Million USD | -95.143% |
| Neurogene Inc. | 36.54 Million USD | -2454.207% |
| Mirum Pharmaceuticals, Inc. | 397.95 Million USD | -134.586% |
| AEON Biopharma, Inc. | 159.88 Million USD | -483.866% |
| CARGO Therapeutics, Inc. Common Stock | 47.65 Million USD | -1859.154% |
| Sesen Bio, Inc. | 30.98 Million USD | -2912.965% |
| Enliven Therapeutics, Inc. | 25.96 Million USD | -3495.921% |
| Kiora Pharmaceuticals, Inc. | 7.6 Million USD | -12179.801% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -376.932% |
| Taysha Gene Therapies, Inc. | 192.05 Million USD | -386.073% |
| Athira Pharma, Inc. | 30.05 Million USD | -3005.889% |
| Vaccinex, Inc. | 5.94 Million USD | -15610.821% |
| HCW Biologics Inc. | 15.05 Million USD | -6102.103% |
| XOMA Corporation | 145.58 Million USD | -541.254% |
| Nektar Therapeutics | 267.04 Million USD | -249.579% |
| Arvinas, Inc. | 644.6 Million USD | -44.824% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -5164.367% |
| Merus N.V. | 102.15 Million USD | -813.879% |
| Omega Therapeutics, Inc. | 146.35 Million USD | -537.88% |
| Quince Therapeutics, Inc. | 95.12 Million USD | -881.431% |
| Rezolute, Inc. | 11.73 Million USD | -7855.829% |
| Clene Inc. | 38.95 Million USD | -2296.696% |
| Indaptus Therapeutics, Inc. | 2.84 Million USD | -32685.824% |
| BeyondSpring Inc. | 48.26 Million USD | -1834.03% |
| Synlogic, Inc. | 32.89 Million USD | -2737.93% |
| Allarity Therapeutics, Inc. | 14.61 Million USD | -6288.401% |
| Phio Pharmaceuticals Corp. | 1.63 Million USD | -57032.007% |
| Peak Bio, Inc. | 20.75 Million USD | -4398.244% |
| Werewolf Therapeutics, Inc. | 63.45 Million USD | -1371.087% |
| Krystal Biotech, Inc. | 39.71 Million USD | -2250.65% |
| Karyopharm Therapeutics Inc. | 376.64 Million USD | -147.857% |
| SpringWorks Therapeutics, Inc. | 99.56 Million USD | -837.578% |
| Lipella Pharmaceuticals Inc. | 432.72 Thousand USD | -215633.975% |
| MannKind Corporation | 721.36 Million USD | -29.412% |
| Ikena Oncology, Inc. | 22.33 Million USD | -4079.704% |
| Cyclerion Therapeutics, Inc. | 2.08 Million USD | -44652.493% |
| Gyre Therapeutics, Inc. | 102.59 Million USD | -809.969% |
| Gossamer Bio, Inc. | 249.14 Million USD | -274.693% |
| CohBar, Inc. | 1.03 Million USD | -90215.662% |
| Cognition Therapeutics, Inc. | 10.68 Million USD | -8633.623% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -4800.971% |
| Legend Biotech Corporation | 589.93 Million USD | -58.245% |
| Mural Oncology plc | 37.92 Million USD | -2361.34% |
| Biora Therapeutics, Inc. | 132.63 Million USD | -603.834% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -40571.11% |
| Disc Medicine, Inc. | 22.87 Million USD | -3981.036% |
| Champions Oncology, Inc. | 28.03 Million USD | -3229.898% |
| REGENXBIO Inc. | 262.22 Million USD | -256.002% |
| Ensysce Biosciences, Inc. | 3.35 Million USD | -27689.199% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -7348.037% |
| Cellectar Biosciences, Inc. | 13.43 Million USD | -6850.29% |
| Edgewise Therapeutics, Inc. | 21.2 Million USD | -4302.438% |
| Vaxart, Inc. | 34.02 Million USD | -2643.68% |
| PharmaCyte Biotech, Inc. | 20.38 Million USD | -4478.571% |
| Aldeyra Therapeutics, Inc. | 28.53 Million USD | -3171.908% |
| Cellectis S.A. | 249.57 Million USD | -274.051% |
| Longeveron Inc. | 5.33 Million USD | -17391.793% |
| Repare Therapeutics Inc. | 41.81 Million USD | -2132.327% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 61.187% |
| Inozyme Pharma, Inc. | 60.36 Million USD | -1446.41% |
| Revolution Medicines, Inc. | 262.39 Million USD | -255.773% |
| Nymox Pharmaceutical Corporation | 2.1 Million USD | -44206.455% |
| Third Harmonic Bio, Inc. | 8.62 Million USD | -10722.363% |
| ArriVent BioPharma, Inc. Common Stock | 11.8 Million USD | -7810.66% |
| AN2 Therapeutics, Inc. | 14.04 Million USD | -6547.703% |
| Anixa Biosciences, Inc. | 2.15 Million USD | -43300.139% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 81.872% |
| Denali Therapeutics Inc. | 122.96 Million USD | -659.202% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -16675.468% |
| Veru Inc. | 32.81 Million USD | -2745.047% |
| Corvus Pharmaceuticals, Inc. | 6.86 Million USD | -13490.581% |
| Cingulate Inc. | 10.36 Million USD | -8910.223% |
| Passage Bio, Inc. | 39.26 Million USD | -2277.711% |
| Context Therapeutics Inc. | 4.19 Million USD | -22171.004% |
| Exicure, Inc. | 8.54 Million USD | -10819.839% |
| Day One Biopharmaceuticals, Inc. | 29.5 Million USD | -3063.674% |
| Oramed Pharmaceuticals Inc. | 10.48 Million USD | -8802.699% |
| Scinai Immunotherapeutics Ltd. | 22.04 Million USD | -4135.457% |
| Rhythm Pharmaceuticals, Inc. | 162.98 Million USD | -472.771% |
| Nuvalent, Inc. | 31.82 Million USD | -2833.529% |
| ABVC BioPharma, Inc. | 6.36 Million USD | -14574.501% |
| Carisma Therapeutics, Inc. | 63.02 Million USD | -1381.287% |
| Unicycive Therapeutics, Inc. | 18 Million USD | -5086.317% |
| OmniAb, Inc. | 87.4 Million USD | -968.12% |
| Anew Medical, Inc. | 8.24 Million USD | -11226.86% |
| Fennec Pharmaceuticals Inc. | 38.28 Million USD | -2338.128% |
| Lipocine Inc. | 2.63 Million USD | -35373.731% |
| Lexeo Therapeutics, Inc. Common Stock | 26.27 Million USD | -3453.353% |
| Nautilus Biotechnology, Inc. | 40.21 Million USD | -2221.538% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -3404.03% |
| G1 Therapeutics, Inc. | 86.15 Million USD | -983.568% |
| Bellerophon Therapeutics, Inc. | 5.4 Million USD | -17184.521% |
| Sage Therapeutics, Inc. | 82.74 Million USD | -1028.182% |
| Ocugen, Inc. | 23.98 Million USD | -3792.495% |
| Mind Medicine (MindMed) Inc. | 46.4 Million USD | -1911.63% |
| Q32 Bio Inc. | 233.12 Million USD | -300.44% |
| Brainstorm Cell Therapeutics Inc. | 9.06 Million USD | -10197.121% |
| Alumis Inc. Common Stock | 53.5 Million USD | -1644.864% |
| Equillium, Inc. | 27.95 Million USD | -3239.189% |
| Kyverna Therapeutics, Inc. | 206.59 Million USD | -351.875% |
| Coya Therapeutics, Inc. | 5.62 Million USD | -16491.302% |
| CNS Pharmaceuticals, Inc. | 6.13 Million USD | -15121.619% |
| Galera Therapeutics, Inc. | 157.32 Million USD | -493.377% |
| Evelo Biosciences, Inc. | 69.43 Million USD | -1244.515% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -9259.517% |
| Dominari Holdings Inc. | 4.63 Million USD | -20041.036% |
| Edesa Biotech, Inc. | 1.84 Million USD | -50590.608% |
| vTv Therapeutics Inc. | 29.56 Million USD | -3057.361% |
| Bio-Techne Corporation | 744.34 Million USD | -25.418% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -640.321% |
| Harmony Biosciences Holdings, Inc. | 344.45 Million USD | -171.018% |
| Prelude Therapeutics Incorporated | 40.57 Million USD | -2200.769% |
| Candel Therapeutics, Inc. | 28.95 Million USD | -3123.873% |
| iTeos Therapeutics, Inc. | 92.36 Million USD | -910.759% |
| Nkarta, Inc. | 105.6 Million USD | -784.031% |
| BioCardia, Inc. | 4.59 Million USD | -20238.497% |
| Iterum Therapeutics plc | 32.66 Million USD | -2758.175% |